Vaxcyte, Inc. (NASDAQ:PCVX) Stock Has Average Price Target of $110.50 According to Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $110.50.

PCVX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Guggenheim raised their price target on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a report on Monday, October 5th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. BTIG Research reiterated a “buy” rating and issued a $89.00 price objective on shares of Vaxcyte in a report on Monday, October 5th. Finally, Bank of America lowered their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research report on Monday, September 28th.

Vaxcyte Stock Down 2.0%

Shares of Vaxcyte stock traded down $1.32 during trading on Thursday, hitting $63.37. 623,298 shares of the stock traded hands, compared to its average volume of 2,025,302. The stock has a market cap of $10.03 billion, a P/E ratio of -7.86 and a beta of 1.31. The company has a fifty day moving average price of $62.24 and a two-hundred day moving average price of $57.65. Vaxcyte has a twelve month low of $42.40 and a twelve month high of $90.75. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.56 and a current ratio of 4.56.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same period last year, the company posted ($1.56) earnings per share. Equities research analysts predict that Vaxcyte will post -7.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Harpreet Dhaliwal sold 17,000 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $67.83, for a total transaction of $1,153,110.00. Following the completion of the sale, the insider owned 68,085 shares in the company, valued at approximately $4,618,205.55. This represents a 19.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.92, for a total value of $182,760.00. Following the transaction, the chief accounting officer directly owned 27,860 shares in the company, valued at approximately $1,697,231.20. This represents a 9.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,692 shares of company stock valued at $5,185,985 over the last quarter. Insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jupiter Topco LLC bought a new position in shares of Vaxcyte in the second quarter valued at approximately $1,044,355,000. Janus Henderson Group PLC grew its stake in Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after buying an additional 3,188,687 shares during the last quarter. BlackRock Inc. acquired a new position in Vaxcyte in the 2nd quarter valued at $701,520,000. Wellington Management Group LLP grew its stake in Vaxcyte by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock valued at $407,001,000 after buying an additional 1,386,968 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Vaxcyte by 150.6% in the 1st quarter. Jennison Associates LLC now owns 1,698,011 shares of the company’s stock worth $98,671,000 after acquiring an additional 1,020,458 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.